Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57604 | 1.00 | MAPK1 (1.00) | MAPK1NOD2ALDH1A1THRBESR1 | |
| SCHEMBL14520991 | 1.00 | MAPK1 (1.00) | MAPK1NOD2ALDH1A1THRBESR1 | |
| SCHEMBL6552473 | 1.00 | MAPK1 (1.00) | MAPK1NOD2ALDH1A1THRBESR1 | |
| SCHEMBL13575286 | 1.00 | MAPK1 (1.00) | MAPK1NOD2ALDH1A1THRBESR1 | |
| SCHEMBL15504324 | 1.00 | MAPK1 (1.00) | MAPK1NOD2ALDH1A1THRBESR1 | |
| SCHEMBL57603 | 1.00 | MAPK1 (1.00) | MAPK1NOD2ALDH1A1THRBESR1 | |
| N-Acetylglucosamine SCHEMBL28342076 | 0.97 | MAPK1 (0.95) | MAPK1NOD2ALDH1A1THRBESR1 | |
| Sulfuric Acid SCHEMBL3262877 | 0.95 | MAPK1 (0.91) | MAPK1NOD2ALDH1A1THRBESR1 | |
| SCHEMBL31124790 | 0.89 | MAPK1 (0.80) | MAPK1NOD2ALDH1A1THRBESR1 | |
| SCHEMBL23247948 | 0.89 | MAPK1 (0.80) | MAPK1NOD2ALDH1A1THRBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413299-B2 | Compositions and methods for treatment of inflammatory disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-05-06 | — | — | US | disclosed |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | THE JOHN HOPKINS UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| WO-2019055597-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TSC | National Tuberous Sclerosis Association, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | National Tuberous Sclerosis Association, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | MAPK1 2051/4885NOD2 11/4885ALDH1A1 3398/4885 |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | TLR4, TLR3, TLR2 | MAPK1 2051/4885NOD2 11/4885ALDH1A1 3398/4885 |
| US-11413299-B2 | Compositions and methods for treatment of inflammatory disorders | TLR4, TLR3, TLR2 | MAPK1 2051/4885NOD2 11/4885ALDH1A1 3398/4885 |
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | MAPK1 2051/4885NOD2 11/4885ALDH1A1 3398/4885 |
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | TLR4, TLR3, TLR2 | MAPK1 1378/4885NOD2 9/4885ALDH1A1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.